Patents Examined by Craig D Ricci
  • External wound-healing agent, and external wound-healing material
    Patent number: 11058660
    Abstract: A method of healing an external wound involves applying an external wound-healing agent to an external wound, or bringing the external wound-healing agent applied to a substrate into contact with an external wound, wherein the external wound-healing agent includes, as an active ingredient, at least one compound of a glycerol alkyl ester represented by defined Formula (I) or a diglycerol alkyl ester represented by defined Formula (II). In a further embodiment, the method involves bringing a fiber aggregate or a film into contact with an external wound, wherein the fiber aggregate or the film each includes a thermoplastic resin and at least one compound of the glycerol alkyl ester or the diglycerol alkyl ester.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: July 13, 2021
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Naosuke Kunimoto, Kenichi Suzuki, Kouya Kojima, Akira Hasegawa, Yasufumi Tsuchiya, Jun Kamada, Satoshi Yamasaki, Goro Kuwamura, Daisuke Hasegawa
  • Use of cytochrome bc1 complex inhibitor in preparing pharmaceutical composition
    Patent number: 11058690
    Abstract: A use of an inhibitor of the cytochrome bc1 complex for preparing a pharmaceutical composition which treats diseases related to smooth muscle spasms, inflammatory diseases, and relieves pain.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 13, 2021
    Assignee: BEIJING WEILANZHIYUAN MEDICAL TECHNOLOGY CO., LTD.
    Inventor: Yuwen Cong
  • Diagnosing and treating colorectal cancer
    Patent number: 11060148
    Abstract: Methods for predicting risk of developing colorectal cancer, for treating colorectal cancer, and reducing risk of developing colorectal cancer.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: July 13, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Matthew Meyerson, Aleksandar Kostic
  • Regimes of FXR agonists
    Patent number: 11052069
    Abstract: The invention provides novel regimens of farnesoid X receptor (FXR) agonist and methods for modulating the activity of farnesoid X receptors (FXRs) using novel regimes of specific FXR agonists, in particular for treating or preventing fibrotic or cirrhotic diseases or disorders, such as liver diseases.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 6, 2021
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Andreas Bauer, Michael Badman, Jin Chen, Patrick Mueller, Rachel Soon
  • Methods of treating heavy menstrual bleeding
    Patent number: 11045470
    Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: June 29, 2021
    Assignee: ABBVIE INC.
    Inventors: Kristof Chwalisz, Laura A. Williams, Rita I. Jain, Janine D. North, Juki Wing-Keung Ng
  • Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same
    Patent number: 11045411
    Abstract: The present invention relates to a process for cosmetic treatment of the skin, comprising the application to the skin of a composition comprising a compound (I) with R, R? and X as defined in the description and S* a monosaccharide or polysaccharide.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 29, 2021
    Assignee: L'OREAL
    Inventors: Maria Dalko, Marie-céline Frantz, Amélie Gueguiniat, Jinzhu Xu, Lisheng Mao
  • Methods of treating fibrosis
    Patent number: 11046641
    Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 29, 2021
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Bioactive material
    Patent number: 11026428
    Abstract: A process and apparatus for manufacture of biocide products are described. The biocide properties arise from the caustic calcined powder, from carbonates such as such as magnesite and dolomite, and from hydroxides such as brucite. The method of manufacture is based on the production of high surface area oxide particles using an indirectly heated counterflow reactors for specifically calcining the carbonates and the hydroxides without significant sintering. The biocide products may be a powder or a hydrated slurry. A hydrated slurry is preferred for agricultural applications as a spray. For aquaculture applications, the products have a preferred particle size distribution to impact the aquatic and benthic ecosystems, and a Ca/Mg ratio that promotes the growth of the cultivates species when applied as a powder or a slurry.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: June 8, 2021
    Assignee: CALIX LTD
    Inventor: Mark Sceats
  • Charged ion channel blockers and methods for use
    Patent number: 11021443
    Abstract: The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 1, 2021
    Assignees: President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Bruce P. Bean, Clifford J. Woolf, Jinbo Lee, Sooyeon Jo, David Roberson, Sebastien Talbot
  • Beta-hydroxybutyrate mixed salt compositions and methods of use
    Patent number: 11020362
    Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts and beta-hydroxybutyric acid are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB composition is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes beta-hydroxybutyric acid and a plurality of BHB salts selected from sodium, potassium, calcium, and magnesium. The BHB composition may include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long chain fatty acid source, vitamin D3, flavorant, or other excipient.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 1, 2021
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Therapeutic agent for dyslipidemia
    Patent number: 11013722
    Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: May 25, 2021
    Assignee: KOWA COMPANY, LTD.
    Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
  • Compositions comprising nanosilica particles and their use in methods of activating T lymphocytes for therapy
    Patent number: 11007217
    Abstract: Compositions comprising silica particles having a mean size by standard particle sizing of between 0.5 nm and 20 nm are described for used in activating lymphocytes in culture or in whole blood.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: May 18, 2021
    Assignee: United Kingdom Research and Innovation
    Inventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria, Rachel Elaine Hewitt, Bradley Michael Vis, Carlos Bastos
  • 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
    Patent number: 11001596
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 11, 2021
    Assignee: Eli Lilly and Company
    Inventors: Renato Alejandro Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Patric James Hahn, Zoran Rankovic
  • 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
    Patent number: 11000525
    Abstract: There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 11, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Tord Bertil Inghardt, Petra Johannesson, Ulrik Jurva, Erik Michaelsson, Eva-Lotte Lindstedt-Alstermark, Nicholas Tomkinson, Jeffrey Paul Stonehouse, Li-Ming Gan
  • Treatment of intrahepatic cholestatic diseases
    Patent number: 11000494
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: May 11, 2021
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Compositions and methods for treating muscular dystrophy and other disorders
    Patent number: 10993954
    Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: May 4, 2021
    Assignee: The Charlotte Mecklenburg Hospital Authority
    Inventors: Qi Long Lu, Marcela Cataldi, Pei Juan Lu
  • Herbicides
    Patent number: 10986838
    Abstract: The present invention relates to herbicidally active pyridino-/pyrimidino-pyridine derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: April 27, 2021
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Neil Brian Carter, Emma Briggs, Kenneth Ling, James Alan Morris, Melloney Morris, Jeffrey Steven Wailes, John Williams
  • Compositions and methods for the treatment of pain
    Patent number: 10987365
    Abstract: The claimed invention relates to compositions that may be in a form of a liquid, solid, gel, cream or gel capsule comprising an analgesic, and methods for administering these compositions for treatment of patients suffering from various forms of pain.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: April 27, 2021
    Assignee: GM Pharmaceuticals, Inc.
    Inventor: Odes W. Mitchell
  • Methods and compositions for the treatment of seizure-related disorders
    Patent number: 10987324
    Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 27, 2021
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, David Chernoff, Sangita Ghosh, Gregory T. Went, Timothy J. Fultz
  • Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
    Patent number: 10973835
    Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: April 13, 2021
    Assignees: The Penn State Research Foundation, Cold Spring Harbor Laboratory
    Inventors: Stephen J. Benkovic, Nicholas K. Tonks, Chun Yu Liu, Navasona Krishnan, Chunliang Liu